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Key Points
• DLBCL patients with
MYC/BCL2 coexpression
demonstrate inferior prognosis
and high-risk gene expression
signatures.
Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal
centerB-cell (GCB)–like andunfavorable activatedB-cell (ABC)–like subtypesbasedongene
expression signatures. In this study,weanalyzed893 de novo DLBCL patients treated with
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). We
show that MYC/BCL2 protein coexpression occurred significantly more commonly in
the ABC subtype. Patients with the ABC or GCB subtype of DLBCL had similar prognoses
with MYC/BCL2 coexpression and without MYC/BCL2 coexpression. Consistent with the
notion that the prognostic difference between the 2 subtypes is attributable to MYC/BCL2
coexpression, there is no difference in gene expression signatures between the 2 subtypes in the absence of MYC/BCL2 coexpression.
DLBCL with MYC/BCL2 coexpression demonstrated a signature of marked downregulation of genes encoding extracellular matrix
proteins, those involving matrix deposition/remodeling and cell adhesion, and upregulation of proliferation-associated genes. We
conclude that MYC/BCL2 coexpression in DLBCL is associated with an aggressive clinical course, is more common in the ABC subtype,
and contributes to the overall inferior prognosis of patients with ABC-DLBCL. In conclusion, the data suggest that MYC/BCL2
coexpression, rather than cell-of-origin classification, is a better predictor of prognosis in patients with DLBCL treated with R-CHOP.
(Blood. 2013;121(20):4021-4031)
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common
type of non-Hodgkin lymphoma and has heterogeneous clinico-
pathological, immunophenotypic, and genetic features. Accord-
ing to the results of gene expression proﬁling (GEP) studies,
DLBCL can be stratiﬁed into germinal center B-cell (GCB)–like or
activated B-cell (ABC)–like subtypes, and patients with the ABC
subtype of DLBCL have an inferior prognosis.1 The GCB and ABC
subtypes have distinctive gene expression signatures. GCB-DLBCL
expresses many genes selectively and/or highly expressed by
normal GCBs, such as CD10 and BCL6. In contrast, ABC-DLBCL
has a gene signature similar to peripheral blood B cells activated in
vitro. Notably, genes upregulated in ABC-DLBCL include MYC,
BCL2, MUM1, CD44, FLIP, and cyclin D2 as well as many other
genes. It is believed that constitutive nuclear factor kB (NF-kB)
activation in ABC-DLBCL drives the expression of this array of
genes and contributes to the ABC phenotype.2 The high NF-kB
activity is attributable to a variety of molecular and genetic mech-
anisms. Mutations of multiple genes have recently been identiﬁed
that encode proteins involved in the signaling of the B-cell receptor
and members of the tumor necrosis factor receptor superfamily,
as well as those involving NF-kB regulation.2,3 Despite the iden-
tiﬁcation of many deregulated target genes in ABC-DLBCL, it
remains unknownwhich gene products at the protein level contribute
most signiﬁcantly to the inferior prognosis of patients with ABC-
DLBCL.
Although the GCB and ABC subtypes convey general trends
regarding clinical outcome, these subtypes do not reliably predict
the prognosis of individual patients. Furthermore, it is impractical
to routinely perform GEP in the clinical setting. Immunohis-
tochemistry (IHC) studies using various antibody panels and
algorithms have been proposed as surrogates for predicting the
GCB vs non-GCB subtype.4-10 The results, however, have been
controversial as the concordance with GEP results is imperfect to
varying degrees and, in some studies, IHC results do not correlate
with prognosis.11-13 Furthermore, both the GCB and ABC subtypes
of DLBCL as deﬁned by GEP are heterogeneous and contain
biological subgroups that have different prognoses and may require
different therapeutic approaches. Therefore, a stratiﬁcation of
DLBCL patients into subgroups that are biologically homolo-
gous and prognostically meaningful, and that are more predictive
than the overall categories of GCB and ABC is needed, thereby
facilitating therapeutic decisions.
Double-hit B-cell lymphoma is deﬁned as a B-cell lymphoma
associated with chromosomal breaks targeting the MYC gene lo-
cated at chromosome 8q24 in combination with additional rear-
rangement affecting another gene, such as BCL2 or BCL6.14 By
far, the most studied type of double-hit B-cell lymphoma has
concurrent MYC and BCL2 breaks (ie, MYC/BCL2 double-hit).
There is a general consensus that patients with MYC/BCL2 double-
hit lymphomas have an extremely aggressive clinical course.14-22
Despite their clinical aggressiveness, almost all cases of MYC/BCL2
double-hit lymphoma are of the GCB subtype, a generally favor-
able prognostic group, illustrating an important discordance between
clinical behavior and cell-of-origin (COO) subtypes.14,16,17
More recently, others have extended the concept of MYC/BCL2
double-hit lymphoma by assessing for MYC and BCL2 protein
expression by IHC, the logic being that protein expression, regardless
of mechanisms, may have prognostic signiﬁcance. In 2 studies, Green
et al and Johnson et al showed that DLBCL patients with MYC/
BCL2 coexpression, with or without MYC or BCL2 gene rearrange-
ments, have a poorer prognosis.23,24 These studies were possible
because of the recent availability of anti-MYC antibodies suitable
for IHC staining in parafﬁn-embedded tissues.
In this study, we used IHC to assess the prognostic value of MYC
and BCL2 expression, and particularly MYC/BCL2 coexpression, in
a large cohort of 893 de novo DLBCL patients treated with R-CHOP
(rituximab, cyclophosphamide, doxorubicin, vincristine, and predni-
sone) therapy. Our results show that MYC/BCL2 coexpression is
associated with a poor prognosis and is more common in ABC-
DLBCL. We further suggest that MYC/BCL2 coexpression ex-
plains the poorer prognosis of patients with ABC-DLBCL and may
be a better predictor of prognosis than COO classiﬁcation.
Materials and methods
Patient selection
We studied 700 cases of de novo DLBCL from patients who were treated with
R-CHOP chemotherapy, including 466 cases in a training set and 234 cases in
a validation set (validation set 1). These cases were organized as a part of the
International DLBCL Rituximab-CHOP Consortium Program study.10,25 All
cases were diagnosed according to World Health Organization (WHO) clas-
siﬁcation criteria. Cases were excluded if patients had a history of low-grade
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B-cell lymphoma, AIDS/HIV infection, primary cutaneous DLBCL, primary
central nervous system DLBCL, and Epstein-Barr virus–positive DLBCL. Only
cases with successful MYC and BCL2 staining were included for further
study. We also used a separate, previously reported validation set (validation
set 2) of 193 cases of de novoDLBCL.23 Therefore, total 893 de novoDLBCL
cases were included and analyzed in this study. The study was reviewed and
approved by the institutional review boards and material transfer agreement
established and approved with each of the participating centers.
Tissue microarray immunohistochemical studies
Hematoxylin-eosin–stained slides from all DLBCL cases were reviewed, and
representative areas with the highest percentage of tumor cells were selected
for tissue microarray (TMA) construction. IHC studies for a variety of markers
were performed using a streptavidin-biotin complex technique on 4-mm TMA
sections. MYC (clone Y69; Epitomics) expression showed a distinct nuclear
pattern and BCL2 (clone 124; DAKO) expression exhibited a cytoplasmic
pattern. A cutoff value for each marker was established from analysis of
receiver-operating characteristic curves to achieve maximum speciﬁcity and
sensitivity as described previously.10 Cutoff values of 40% for MYC and 70%
for BCL2 were established. These values were similar to those in a previous
study, in which median values were used as the cutoff values.23 For all other
markers assessed in this study, cutoff values have been described previously.10
FISH for MYC and BCL2 and sequencing of TP53
Fluorescence in situ hybridization (FISH) analysis was performed using
formalin-ﬁxed parafﬁn-embedded (FFPE) tissue sections of all 466 cases
in the training set using BCL2 dual-color breakapart probes (Vysis) as
described previously.10MYCwas assessed by FISH using locus-speciﬁc IGH/
MYC/CEP8 tricolor dual-fusion probes and locus-speciﬁc MYC dual-color
breakapart probes (Vysis). Cases were considered for evaluation if at least 200
tumor cell nuclei per core displayed positive signals in the TMA sections. For
TP53 sequencing, genomic DNA and total RNA were extracted from FFPE
tissue of all cases in the training set and processed as previously described.25
Gene expression profiling
Total RNA was extracted from FFPE tissue samples of 451 cases in the
training set using the HighPure Parafﬁn RNA Extraction Kit (Roche
Table 1. Clinicopathological characteristics and outcome of DLBCLs treated with R-CHOP
Overall DP Non-DP
P valueN (%) OS, P PFS, P N (%) N (%)
Patients 466 (100) 157 (100) 309 (100)
Gender
Male 272 (58) .7477 .4730 90 (57) 182 (59) .7445
Female 194 (42) 67 (43) 127 (41)
Age
#60 194 (42) .0004 .0016 49 (31) 145 (47) .0011
.60 272 (58) 108 (69) 164 (53)
B symptoms*
Absence 276 (68) .0015 .0014 88 (62) 188 (72) .0541
Presence 127 (32) 53 (38) 74 (28)
ECOG performance status*
,2 350 (88) ,.0001 ,.0001 111 (83) 239 (90) .0453
$2 50 (12) 23 (17) 27 (10)
Stage*
I-II 219 (49) ,.0001 ,.000l 50 (33) 169 (57) ,.0001
III-IV 228 (51) 100 (67) 128 (43)
Extranodal sites*
,2 346 (78) ,.0001 ,.000l 106 (72) 240 (82) .0160
$2 96 (22) 42 (28) 54 (18)
Lactate dehydrogenase*
Normal 168 (40) .0003 ,.000l 51 (36) 117 (42) .2908
Elevated 252 (60) 89 (64) 163 (58)
IPI risk group*
0-2 263 (64) ,.000l ,.0001 70 (51) 193 (70) .0001
3-5 148 (36) 67 (49) 81 (30)
Tumor size, cm*
,7.5 253 (77) .0100 .0172 81 (73) 172 (79) .2587
$7.5 77 (23) 30 (27) 47 (21)
Treatment response
CR 354 (76) ,.000l ,.000l 103 (66) 251 (84) ,.0001
Others 112 (24) 54 (34) 48 (16)
COO classification
GCB 241 (52) .0080 .0075 53 (34) 188 (61) ,.0001
ABC 225 (48) 104 (66) 121 (39)
Ki-67*
,7O 158 (34) .2998 .3434 41 (26) 117 (38) .0086
$70 304 (66) 116 (74) 188 (62)
TP53 mutations
Absence 357 (77) 117 (75) 240 (78) .4480
Presence 109 (23) .0005 .0004 40 (25) 69 (22)
DP, MYC/BCL2 double positive by IHC; ECOG, Eastern Cooperative Oncology Group; Non-DP, non-MYC/BCL2 double positive.
*Information not available in some cases.
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Applied Science) and subjected to GEP as described previously.10 For data
analysis and classiﬁcation, the microarray DQN signals were generated and
normalized to the quantiles of b distribution with parameters P 5 1.2 and
q 5 3. DQN is an ideal expression algorithm used for expression microarray
analysis and represents the non-central trimmed mean of differences between
perfect match and mismatch intensities with quantile normalization. A
Bayesian model was also used to determine the classiﬁcation probability.26
The GEP classiﬁcation method developed from this study was validated with
Figure 1. Prognostic impact of MYC/BCL2 coexpression in DLBCL. (A-B) OS (A) and PFS (B) of patients with DLBCL with MYC/BCL2 coexpression (MYC1BCL21) in the
training set. (C-D) OS of patients with MYC1 DLBCL in the presence (C) or absence (D) of BCL2 coexpression in the training set. (E-F) OS of patients with BCL21 DLBCL in
the presence (E) or absence (F) of MYC coexpression in the training set.
Figure 2. Prognostic impact of MYC/BCL2 coexpression in DLBCL risk-stratified according to clinicopathologic parameters. (A-B) OS (A) and PFS (B) of patients
with MYC1BCL21 DLBCL of the GCB subtype in the training set. (C-D) OS (C) and PFS (D) of patients with MYC1BCL21 DLBCL of the ABC subtype in the training set.
(E-F) OS (E) and PFS (F) of patients with MYC1BCL21 DLBCL risk-stratified according to IPI risk scores in the training set. DP, MYC/BCL2 double-positive; Non-DP,
non–double positive.
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an independent Leukemia Lymphoma Molecular Proﬁling Program
dataset in the Gene Expression Omnibus database GSE1084627 with 181
CHOP-treated and 233 R-CHOP–treated DLBCL patients and achieved
over 97% concordance rate for the classiﬁcation of 2 subtypes (GCB and
ABC).
COO classification
COO classiﬁcation was achieved by combining GEP and IHC data,
with the GEP data considered the “gold standard.” Brieﬂy, IHC was
performed in all cases in the training set and validation set 1. GEP was
performed in 451 cases in the training set and 411 were classiﬁed as
GCB or ABC; 40 (9%) were unclassiﬁable. The classiﬁcation of these
411 cases was based on the GEP results regardless of IHC results. The
40 cases not classiﬁable by GEP and 15 additional cases in the training
set, for which GEP was not performed, as well as all cases in validation
set 1 were classiﬁed by IHC methods according to both the Visco-Young
and Choi algorithms (supplemental Figure 6, available on the Blood
Web site).10 The COO classiﬁcation of validation set 2 was previously
reported.23
Statistical analysis
Statistical analyses were performed as described in supplemental Materials
and methods. The outcome analyses were based on the entire training set of
466 cases. The outcome analysis results limited to the 411 cases stratiﬁed
by GEP were strikingly similar to those derived from the entire training set
and are shown in supplemental Figures 1-5.
Results
The clinical and pathological features of 466 cases in the
training set are listed in Table 1. Two hundred forty-one (52%)
cases were classiﬁed as the GCB subtype and 225 (48%) were
classiﬁed as the ABC subtype (Table 1). The median follow-up
time for this study cohort was 57 months.
MYC/BCL2 protein coexpression predicts poor prognosis
in DLBCL
Using cutoff values of 40% and 70% positive tumor cells for
MYC and BCL2, respectively, 300 (64%) were positive for MYC
and 233 (50%) cases were positive for BCL2. One hundred ﬁfty-
seven (34%) were positive for both MYC and BCL2 and 90
(19%) were negative for both.
MYC and BCL2 protein coexpression in DLBCL had a
signiﬁcant adverse impact on patient survival (Figure 1A-B).
The 5-year overall survival (OS) of DLBCL patients with
MYC/BCL2 coexpression vs all other patients was 30% vs 75%
(P, .0001); the 5-year progression-free survival (PFS) was 27% vs
73% (P , .0001). When assessed separately, patients with MYC1
or BCL21 DLBCL had signiﬁcantly inferior OS (Figure 1C,E)
and PFS (data not shown) compared with patients with MYC-
negative or BCL2-negative DLBCL, respectively. However, the
prognostic impact of MYC or BCL2 protein expression was ap-
parently due to the confounding effect of cases with MYC/BCL2
coexpression. When all cases with MYC/BCL2 coexpression were
excluded, neither MYC nor BCL2 protein expression signiﬁcantly
impacted OS (Figure 1D,F) and PFS. Similarly, MYC or BCL2
protein expression did not correlate with COO subtypes (data not
shown).
Stratifying all patients into GCB and ABC subtypes, patients
with DLBCL with MYC/BCL2 coexpression had signiﬁcantly worse
OS and PFS within both COO subtypes (Figure 2A-D). The
prognostic impact of MYC/BCL2 coexpression in DLBCL was
further assessed according to various clinical parameters. The
signiﬁcantly worse OS and PFS conferred by MYC/BCL2 coex-
pression were observed in both low- and high-risk subgroups of
DLBCL stratiﬁed by International Prognostic Index (IPI) scores
(Figure 2E-F) and other individual clinical parameters (supple-
mental Figure 7).
The adverse prognostic impact of MYC/BCL2 coexpression in
DLBCL and its COO subtypes was validated in an independent set
of 234 cases (validation set 1) of de novo DLBCL treated with R-
CHOP (supplemental Figure 8). In multivariate analysis, controlling
for other clinicopathological parameters, MYC/BCL2 coexpres-
sion remained a strong independent predictor of OS (P , .0001)
and PFS (P , .0001) in DLBCL patients (Table 2).
MYC/BCL2 coexpression is associated with high-risk
clinical parameters
Various clinicopathological parameters were compared between
patients with DLBCL with or without MYC/BCL2 coexpression
(Table 1). Patients with DLBCL with MYC/BCL2 coexpression
had multiple adverse prognostic factors included in the IPI risk
stratiﬁcation, including advanced age (P 5 .0011), high-stage
Table 2. Multivariate analysis of clinicopathological parameters in
DLBCLs treated with R-CHOP
OS PFS
HR 95% CI P HR 95% CI P
B symptoms 1.47 1.04-2.09 .0310 1.45 1.03-2.03 .0314
Tumor size, $7.5 cm 1.22 0.87-1.71 .2467 1.21 0.86-1.69 .2708
IPI risk, .2 2.38 1.67-3.38 ,.0001 2.22 1.59-3.11 ,.0001
COO classification, ABC 1.17 0.79-1.72 .4329 1.18 0.82-1.71 .3750
TP53 mutation 1.72 1.17-2.52 .0057 1.63 1.12-2.37 .0105
MYC/BCL2 coexpression 2.52 1.73-3.67 ,.0001 2.45 1.71-3.51 ,.0001
CI, confidence interval; HR, hazard ratio.
Figure 3. Frequency of BCL2 and MYC expression
in COO subtypes of DLBCL. (A) Relative frequency of
the ABC vs GCB subtype in DLBCL positive for BCL2
expression, MYC expression, or MYC/BCL2 coexpression
in the training set. (B) Frequency of BCL2 expression, MYC
expression, or MYC/BCL2 coexpression (in the presence
or absence of MYC/BCL2 corearrangements, DH) in
DLBCL of the ABC and GCB subtypes in the training set.
DH, double hit.
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disease (P , .0001), poor performance status (P 5 .0453), and
multiple extranodal sites of disease (P 5 .0160). Consequently,
more patients with DLBCL with MYC/BCL2 coexpression had
an intermediate-high to high IPI score (P 5 .0001). Patients with
DLBCL with MYC/BCL2 coexpression were also associated with
a lower rate of complete remission (P , .0001) and a higher pro-
liferation index (P 5 .0086). There was no signiﬁcant difference
in gender, serum lactate dehydrogenase level, tumor size, or
Figure 4. MYC/BCL2 coexpression contributes to the inferior prognosis of ABC-DLBCL. (A-B) OS (A) and PFS (B) of the ABC vs GCB subtype of DLBCL
in the entire training set. COO classification of 411 cases was based on GEP results and 55 cases based on IHC results. (C-D) OS (C) and PFS (D) of the ABC vs
GCB subtype of DLBCL after all MYC1BCL21 cases were excluded. (E-F) OS (E) and PFS (F) of the ABC vs GCB subtype in MYC1BCL21 DLBCL.
Figure 5. Prognostic impact of MYC/BCL2 coexpression in DLBCL is independent of MYC/BCL2 corearrangement and TP53 mutation status. (A-B)
OS (A) and PFS (B) of patients with MYC/BCL2 double-hit DLBCL. (C-D) OS (C) and PFS (D) of patients with MYC1BCL21 DLBCL in the absence of
MYC/BCL2 double hit. (E) OS of patients with MYC1BCL21 DLBCL in the absence of TP53 mutation. (F) Prognostic impact of TP53 mutation in MYC1BCL21
DLBCL.
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frequency of TP53 mutations between DLBCL patients with or
without MYC/BCL2 coexpression.
MYC/BCL2 coexpression shows ABC predominance and
contributes to the inferior prognosis of ABC-DLBCL
The presence of MYC/BCL2 coexpression correlated signiﬁcantly
with the ABC subtype (P , .0001) (Table 1). Of 157 cases of
DLBCL with MYC/BCL2 coexpression, 104 (66%) were ABC-
DLBCL (Figure 3A and Table 1). By contrast, only 121 of 309
(39%) of DLBCL without MYC/BCL2 coexpression were ABC-
DLBCL (Table 1). Approximately 46% (104 of 225) of ABC-
DLBCL had MYC/BCL2 coexpression compared with 22% (53
of 241) of GCB-DLBCL with MYC/BCL2 coexpression (P ,
.0001) (Figure 3B). In cases only stratiﬁed by GEP, 49% of ABC-
DLBCL and 19% of GCB-DLBCL showed MYC/BCL2 coex-
pression (supplemental Figure 3). Considering BCL2 and MYC
protein expression individually, ABC-DLBCL had a signiﬁcantly
higher frequency of BCL2 (61% vs 40%; P , .0001) and MYC
(72% vs 57%; P 5 .0009) expression than GCB-DLBCL
(Figure 3B).
In the training set, ABC-DLBCL was associated signiﬁ-
cantly with inferior OS (P 5 .0080) and PFS (P 5 .0075)
(Figure 4A-B). However, after excluding all cases with MYC/
BCL2 coexpression, the prognosis of patients with ABC-DLBCL
was similar to that of patients with GCB-DLBCL (OS: P 5 .3163;
PFS: P 5 .4291) (Figure 4C-D). This result was validated in a
previously reported independent cohort (supplemental Figure 9).
Considering only patients with DLBCL with MYC/BCL2 coex-
pression, there was no signiﬁcant difference in OS (P 5 .4114)
or PFS (P 5 .7020) between the ABC and GCB subtypes
(Figure 4E-F).
When analysis was limited to the 411 cases classiﬁed by GEP
data, similar results were observed (supplemental Figure 4). Con-
sistent with these results, in multivariate analysis, after control-
ling for MYC/BCL2 coexpression, the ABC subtype was not
a signiﬁcant prognostic predictor of OS (P 5 .4329) or PFS
(P 5 .3750) (Table 2). These data support the notion that the
inferior clinical outcome of patients with ABC-DLBCL is attribut-
able to a signiﬁcantly higher frequency of cases with MYC/BCL2
coexpression.
MYC/BCL2 coexpression confers an adverse prognostic impact
independent from MYC/BCL2 corearrangement and TP53
mutation status
Approximately 3% (10 of 394) of DLBCL cases in the training set
had concurrent MYC and BCL2 rearrangements; 9 of them were
of the GCB subtype. DLBCL with MYC/BCL2 corearrangement
was associated with markedly poor OS (P , .0001) and PFS
(P , .0001) (Figure 5A-B). By IHC, 8 of these cases exhibited
MYC/BCL2 coexpression and the other 2 cases were positive for
either MYC or BCL2.
The remaining 384 cases (199 ABC and 185 GCB) in the
training set lacked concurrent MYC/BCL2 rearrangements; 124
(32%) had MYC/BCL2 coexpression. In the absence of MYC/
BCL2 corearrangement, MYC/BCL2 coexpression showed a
marked predilection for the ABC subtype: 47% (93 of 199) vs
17% (31 of 185) in the GCB subtype (P, .0001) (Figure 3B) and
remained a signiﬁcant predictor of inferior OS (P , .0001) and PFS
(P , .0001) (Figure 5C-D). Similarly, MYC/BCL2 coexpression
predicted inferior survival in the absence of TP53 mutations
(Figure 5E). However, TP53mutation remained a signiﬁcant pro-
gnostic factor in patients with DLBCL with MYC/BCL2 coex-
pression (Figure 5F).
MYC/BCL2 coexpression contributes to different gene
expression signatures of GCB and ABC-DLBCL
The above data show that the poorer prognosis of patients with
ABC-DLBCL can be attributed, in large part, to the higher
frequency of cases with MYC/BCL2 coexpression in the ABC
subtype. We compared GEP results between the ABC and GCB
subtypes with MYC/BCL2 coexpression (Figure 6; supplemen-
tal Table 1). A total of 208 genes were differentially expressed
(P , .001), including 121 genes highly expressed in the GCB
subtype and 87 genes highly expressed in the ABC subtypes. As
expected, the gene signatures of the ABC vs GCB subtype of
DLBCL with MYC/BCL2 coexpression largely reﬂected those
reported by Alizadeh et al.1 The notable genes included CD10,
Figure 6. MYC/BCL2 coexpression contributes to the different gene expression
profiles between GCB and ABC subtypes of DLBCL. (A) GEP comparison between
the ABC vs GCB subtype of DLBCL with MYC/BCL2 coexpression. Of 157 cases of
MYC1BCL21DLBCL, GEP was successfully performed in 149 cases (ABC: 102; GCB:
47).DP,MYC/BCL2doublepositive.A total of 208genescorresponding to365probesets
were differentially expressed (P , .001). (B) GEP comparison between the ABC (30
cases) vs GCB (58 cases) subtype of DLBCL negative for both MYC and BCL2 protein
expression. A total of 20 genes corresponding to 30 probesets were differentially
expressed between the 2 COO subtypes (P, .01). DN, MYC/BCL2 double negative.
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BCL6, MYBL1, and PI3KCG in the GCB subtype vs MUM1,
cyclin D2, FLIP, CD44, and SLAP in the ABC subtype. Addi-
tionally, we also identiﬁed many genes that have been shown to
be differentially expressed between the 2 COO subtypes and confer
prognostic impact by others, such as REL and CIITA in GCB-
DLBCL, and CARD11, IGHM, FOXP1, and SPIB in ABC-DLBCL
(supplemental Table 1).2,28-32
We further compared GEP results between the ABC and GCB
subtypes in cases negative for both MYC and BCL2 expression
(Figure 6B; supplemental Table 2). Surprisingly, there were no
genes differentially expressed between the 2 subtypes at the same
signiﬁcance level of P , .001 and only a few genes at a sig-
niﬁcance level of P , .01. A total of 20 genes were differentially
expressed between the 2 subtypes, including 12 highly expressed
in the GCB and 8 highly expressed in the ABC subtype. Thirteen
of these 20 genes were also differentially expressed between the 2
subtypes with MYC/BCL2 coexpression. However, only a few
genes (AFF2/FMR2, FOXP1, and PIM2) were among those pre-
viously found to be differentially expressed between the 2 COO
subtypes.1,32
Gene expression signature of DLBCL with MYC/BCL2
coexpression
To elucidate the potential molecular basis behind the aggres-
sive clinical course of patients with DLBCL with MYC/BCL2
coexpression, we compared GEP results of DLBCL with MYC/
BCL2 coexpression with those of DLBCL negative for both MYC
and BCL2 expression (Figure 7; supplemental Table 3). A total of
153 genes were differentially expressed, including 65 genes upreg-
ulated and 88 genes downregulated in DLBCL with MYC/BCL2
coexpression (P , .001).
The most striking ﬁnding in DLBCL with MYC/BCL2 coex-
pression was the downregulation of a large number of genes (33 of
88 or 38%) encoding various extracellular matrix (ECM) proteins
or those involving the ECM deposition and remodeling (Table 3;
supplemental Table 3). The ECM-encoding genes included those
encoding various subtypes of collagen, ﬁbronectin, versican,
thrombospondin, SPARC, and biglycan. The ECM remodeling
genes included metallopeptidase/serine proteases and their inhib-
itors and matrix-associated proteins. Those genes involving the
production of ECM included FGFR1 and FAP. Another prominent
feature was the downregulation of genes (21 of 88, 24%) involved
in cell adhesion, motility, and cytoskeletal organization, such as
integrins, CD58, cortactin, caldesmon, calponin, and tropomyosin.
Of the genes up-regulated in DLBCL with MYC/BCL2 coex-
pression, 20 encoded proteins involved in cell proliferation, including
MYC and BCL2 as expected, as well as TCL1A, MLL, FOXP1, SP1B,
TCF4, TNFRSF13B, and those promoting DNA and protein synthesis
(Table 3; supplemental Table 3). Chromosomal breakpoints involving
the TCL1A and MLL genes deﬁne T-prolymphocytic leukemia and
a subtype of acute myeloid leukemia, respectively. FOXP1 and SPIB
are transcriptional factors ampliﬁed in the ABC-DLBCL.32 Mutations
of TCF4, a component of the Wnt pathway, have been shown in
various types of solid tumors and lymphoma/leukemia. TNFRSF13B
signaling activates NF-kB, NF-AT, and AP1. POLR3G and POLR1B
are DNA-dependent RNA polymerases.
Discussion
In this study, we show that patients with DLBCL characterized by
MYC/BCL2 coexpression have a poor clinical outcome with a
5-year OS and PFS of ,30%. MYC/BCL2 coexpression in DLBCL
is also a strong predictor of poor prognosis in the 2 COO subtypes.
Patients with DLBCL with MYC/BCL2 coexpression have many
clinicopathological features associated with adverse prognosis,
including older age, advanced stage of disease, multiple extranodal
sites of involvement, high IPI score, high proliferation index, and
poor treatment response. Approximately one-third of DLBCL
demonstrate MYC/BCL2 coexpression, in keeping with the 29%
frequency reported in an earlier study by Green et al.23 By contrast,
MYC/BCL2 double-hit B-cell lymphoma characterized by chro-
mosomal breaks involving MYC and BCL2 is a rare disease,
representing ;3% of all DLBCL cases in our study. Thus, the
ﬁndings in this study expand the spectrum of aggressive DLBCL,
deﬁned previously at the genetic level, by using the immunohis-
tochemical approach. In our study, we observed an overall MYC1
rate of 64% and MYC1BCL21 34% in our training set and an
overall MYC1 rate of 54% and MYC1BCL21 32% in our val-
idation set, which were in line with the overall MYC1 rate of 54%
and MYC1BCL21 rate of 29% observed by Green et al23 (personal
Figure 7. Gene expression signature of DLBCL with MYC/BCL2 coexpression.
Comparison of GEPs of DLBCL with MYC/BCL2 coexpression (149 cases) vs
DLBCL negative for MYC and BCL2 expression (88 cases). A total of 153 genes
corresponding to 219 probe sets were differentially expressed (P , .001).






ECM, ECM production and
remodeling
33 COL3A1, VCAN, TNS1, FN1, THBS2,
TIMP3, SPARC, SULF1, SPINK2,
MMP2, ADAM12, FGFR1, FAP
Cell adhesion and cytoskeletal
organization
21 CD11A/CD11B, CD58, THY1, RFTN1,
ANTXR1, RHOB, MICAL2
Cell growth regulation 16 LM02, TRAF1, CDK14, SGK1, RGS1,
NBL, PDE4D
Others, including unknown 18 PSAP, LYZ, LOC115110, ZNF662
Upregulated genes
Cell proliferation 20 MYC, BCL2, TCL1A, MLL, FOXP1,
SPIB, TCF4, TNFRSF13B,
PMDAIP1, GAB1, PLOR3G
Cell metabolism 5 DCTPP1, CYB5R2, HK2, TMEM97,
CYB5R2
Miscellaneous cell functions 13 PPIL1, PIGW, FUT8, SPINK5
Unknown 27 KIAA0664, C9orf91, ZNF107
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communication and legends of supplemental Figures 8 and 9), but
higher than those reported by Johnson et al.24 The cause of the
discrepancy is not known.
ABC-DLBCL, as stratiﬁed by gene expression signatures, is
associated with a poor prognosis compared with GCB-DLBCL.1
The inferior prognosis of patients with the ABC-DLBCL has been
attributed to constitutive NF-kB activity, leading to the upregula-
tion of a number of NF-kB target genes, including MYC and
BCL2.2 At the protein level, we show here that MYC/BCL2
coexpression is more frequently observed in the ABC subtype. We
suggest that the high frequency of MYC/BCL2 coexpression in
ABC-DLBCL greatly contributes to the overall poor prognosis of
this patient subset. Our data support this statement in 3 ways. First,
there was no signiﬁcant prognostic difference between DLBCL
patients with the GCB vs ABC subtype when all cases with MYC/
BCL2 coexpression were excluded. Second, when only patients
with DLBCL with MYC/BCL2 coexpression were considered, the
2 subtypes did not confer signiﬁcant prognostic difference either.
Third, although there was a striking difference in gene signatures
between the ABC and GCB subtypes with MYC/BCL2 coex-
pression, the difference in gene signatures between the 2 subtypes
was minimal in MYC/BCL2 double-negative DLBCL. We found
this result somewhat surprising given that the GCB and ABC
subtypes of DLBCL are assumed to be derived from B cells at
different differentiation stages. We found that MYC/BCL2 double-
negative DLBCL had a higher percentage of cases unclassiﬁable
by GEP or that showed a discordance between GEP and IHC-based
classiﬁcation (30% in MYC/BCL2 double-negative group vs
19% in DLBCL with MYC/BCL2 coexpression; P 5 .07). These
borderline cases may blur the boundary between the GCB and
ABC signatures. There are at least 5 distinct subsets of mature
B cells corresponding to different B-cell differentiation stages33
and it is possible that DLBCL could be derived from each of these
subsets. Our results raise the issue as to whether it is appropriate
to “force” DLBCL cases into a binary and perhaps overly sim-
plistic classiﬁcation.
Our results show that DLBCL with MYC/BCL2 coexpres-
sion is a unique subset of DLBCL with dismal clinical out-
come. The potential molecular basis behind the dismal outcome
is seen through the gene expression proﬁles of cases with MYC/
BCL2 coexpression: stromal, adhesion, and proliferation signatures.
The stromal signature is similar to what was described by Lenz et al
(stromal signature 1) although it is more striking in DLBCL
with MYC/BCL2 coexpression.27 Both stroma-poor and proliferation
signatures are associated with poor prognosis in DLBCL.27,28,34,35 A
cell-adhesion signature has not been described in lymphoma to
date although its role in the invasion of solid tumors is well-
established.36 Presumably, the lack of cell-cell and cell-matrix
adhesions might play a role in the high frequency of advanced
stage of disease and involvement of multiple extranodal sites in
DLBCL with MYC/BCL2 coexpression.
However, we do not wish to imply that there are no other
pathogenetic factors that contribute to the inferior prognosis of
patients with ABC-DLBCL, nor are we suggesting that the ABC
and GCB subtypes of DLBCL with MYC/BCL2 coexpression are
biologically homogeneous. Each of these subtypes might include
additional subsets with additional predictive prognostic factors
that deserve further investigation. Our GEP studies clearly show
heterogeneity in the group of DLBCL with MYC/BCL2 coexpression.
Instead, we only wish to emphasize that MYC/BCL2 coexpression
has signiﬁcant prognostic value for DLBCL patients and these
tumors represent almost half of the ABC-DLBCL cases. In addition,
the recognition of DLBCL with MYC/BCL2 coexpression expands
the spectrum of aggressive B-cell lymphomas for which novel
therapies are needed, and IHC assessment for MYC and BCL2
expression provides a practical approach to effectively stratify
DLBCL into prognostically relevant subgroups.
With regard to the prognostic impact of BCL2 expression
alone in DLBCL in the era of R-CHOP chemotherapy, previous
studies reported inconsistent results.21,23,24,37-44 Most of these
studies had small patient cohorts and/or also did not address the
confounding effects of other factors, such as MYC expression. In
this study, we found that BCL2 expression predicted survival in
DLBCL in the overall patient cohort and in the COO subtypes.
However, the observed prognostic impact of BCL2 expression
was attributable to the subset of DLBCL cases with MYC/
BCL2 coexpression. Similarly, MYC protein expression affected
prognosis only in the presence of BCL2 coexpression, consistent
with the studies by Johnson et al.24 Approximately 60% of cases
with BCL2 but without concurrent MYC rearrangement demon-
strated MYC protein expression in our cohort. This may explain
our previous observation that DLBCL with BCL2 rearrangement
showed worse prognosis irrespective of MYC rearrangement
status.45
In summary, DLBCL with MYC/BCL2 coexpression character-
izes a subset of DLBCL patients with high-risk gene signatures,
high-risk clinicopathological features and poor prognosis. DLBCL
with MYC/BCL2 coexpression apparently expands the spectrum of
MYC/BCL2 double-hit B-cell lymphoma deﬁned genetically and
well-recognized to have a poor prognosis. However, it should be
emphasized that our data do not show that MYC/BCL2 double-hit
B-cell lymphoma and DLBCL with MYC/BCL2 coexpression are
equivalent. It is possible that additional molecular abnormalities or
levels of MYC and BCL2 protein expression may distinguish these
2 groups. We further show that DLBCL with MYC/BCL2 coex-
pression occurs in almost half of ABC-DLBCL cases and appears
to account, in large part, for the inferior prognosis of patients with
ABC-DLBCL. These data also suggest that assessment for MYC
and BCL2 protein expression more reliably predicts prognosis than
the COO classiﬁcation.
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